Targeting the dopamine D2 receptor in schizophrenia (Q36539461)

14 August 2017

1 reference

title

Targeting the dopamine D2 receptor in schizophrenia (English)

1 reference

14 August 2017

0 references

Philip Seeman

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Therapeutic Targets

14 August 2017

published in

1 reference

14 August 2017

volume

10

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

515-531

1 reference

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Dopamine receptor blockade by neuroleptic drugs inAplysia neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Receptor activity and turnover of dopamine and noradrenaline after neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Brain receptors for antipsychotic drugs and dopamine: direct binding assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Antipsychotic drug doses and neuroleptic/dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Multiple receptors for dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Elevation of prolactin levels by atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Clinical outcome and olanzapine plasma levels in acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

An update of fast-off dopamine D2 atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Dopamine D3 receptor antagonists as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Provocative tests with psychostimulant drugs in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Stimulant psychosis: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Historical development of the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Radiosynthesis and evaluation of [11C]-( )-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-( )-PHNO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.10.4.515

10.1517/14728222.10.4.515

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference